Recently, the checkpoint inhibitors/antibodies, such as PD-1/PD-L1 antibodies have been observed to enhance the tumor suppressor activity of T immune cells in solid tumors including advanced NSCLC, and have shown very promising results in multiple cancers in many clinical trials. This evidence concerns the gene PDCD1 and cancer.